APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Status:
Active, not recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
This clinical trial is a Phase I, open-label, dose-finding and cohort expansion study to
determine the safety and preliminary efficacy of APR-246 in combination with venetoclax and
azacitidine in patients with myeloid malignancies.